Citations

Institution: Mayo Clinic Clear

Showing 10 of 108015 citations.

Artificial Intelligence in Clinical Gastroenterology: Promise, Pace, and Proof
Stidham, Ryan W. , Stidham, Ryan W

American Journal of Gastroenterology | April 3, 2026 | Volume: 121 | Issue: 4 | Pages: 811-812

10.14309/ajg.0000000000003972 | PMID 41930835 Get It

A Resident's Guide to Matching Into Gastroenterology Fellowship
Alsakarneh, Saqr , Dahiya, Dushyant Singh

ACG Case Reports Journal | April 3, 2026 | Volume: 13 | Issue: 4 | Pages: No page available

10.14309/crj.0000000000002037 | PMID 41937907 Get It

Abstract 5051: A multi-center hospital-based case-control study of lymphoid and myeloid neoplasms (AsiaLymph): Study design and initial findings for education, body mass index, and family history
Lan, Qing, Chan, John K., Lam, Tai Hing , Chen, Kexin, Kwong, Yok Lam, Xu, Caigang , Chiu, Brian CH, Liang, Raymond , Dennis, Ip, Hu, Wei, Bassig, Bryan A. , Purdue, Mark, Xu, Jun, Locke, Sarah J. , Wang, Sophia S., Berndt, Sonja, Hofmann, Jonathan N., Shi, Jianxin , Yu, Kai, Gadalla, Shahinaz, Jones, Rena, Dai, Hongji, Lyu, Zhangyan, Qiu, Lugui , Liu, Wei, zhang, huilai, Wang, Xianhuo, Chanock, Stephen, Linet, Martha, Vermeulen, Roel, Rothman, Nathaniel, Lan, Qing , Hurwitz, Lauren M. , Chan, John K.C., Chen, Kexin , Chiu, Brian C.‐H. , Cerhan, James R. , Hofmann, Jonathan N. , Gadalla, Shahinaz M. , McReynolds, Lisa J. , Jones, Rena R. , Qiu, Lugui , Liu, Wei , Zhang, Huilai , Wang, Xianhuo , Morton, Lindsay M. , Linet, Martha S. , Friesen, Melissa C. , Vermeulen, Roel , Rothman, Nathaniel

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 5051-5051

10.1158/1538-7445.am2026-5051 Get It

Abstract Background: Epidemiologic and other studies have identified environmental, occupational, and genetic risk factors for lymphoid and myeloid malignancies, but most studies have been conducted in Western populations. Investigations in populations with differing exposure patterns, distributions of disease subtypes, and genetic architecture are needed to fully understand hematopoietic tumor etiology. Methods: We conducted a large, multicenter, hospital-based case-control study of lymphoid and myeloid neoplasms in East Asia (AsiaLymph), including 5,671 lymphoid cases, 1,879 myeloid cases, and 3,858 controls. Participants completed a computer-assisted personal interview and provided biospecimens. Cases underwent central pathology review and were coded into the WHO Classification. Herein, we describe the study methods in detail and report association results for education, body mass index, and family history. Results: Greater BMI at age 20 but not at age 40 was associated with odds of total lymphoid neoplasm (per 5 kg/m2 increase: OR [95% CI]: 1.18 [1.09-1.27]), total myeloid neoplasm (OR [95% CI]: 1.17 [1.05-1.29]), and several subtypes. Greater educational attainment was associated with increased odds of total lymphoid neoplasm (for college vs. less than primary education: OR [95% CI]: 1.41 [1.21-1.65]) but not myeloid neoplasm (OR [95% CI]: 1.17 [0.95-1.45]; p-heterogeneity=0.02). There were also positive associations between family history of hematologic cancer in first degree relatives and odds of lymphoid neoplasm (OR [95% CI]: 1.53 [1.15-2.03]) and myeloid neoplasm (OR [95% CI]: 1.65 [1.11-2.44]) and specific subtypes. None of the evaluated risk factors were associated with NK/T-cell lymphoma, which supports a distinct etiology for this subtype. Conclusion: The AsiaLymph Study is one of the largest molecular epidemiology studies of both lymphoid and myeloid neoplasms with standardized World Health Organization classification of histopathologic subtypes and will serve as a valuable resource for etiologic investigations into risk factors for these malignancies. Citation Format: Qing Lan, Lauren M. Hurwitz, John K. Chan, Tai Hing Lam, Kexin Chen, Yok Lam Kwong, Xu Caigang, Brian CH Chiu, Raymond Liang, Ip Dennis, Wei Hu, Bryan Bassig, Mark Purdue, Jun Xu, Sarah Locke, Sophia S. Wang, James R. Cerhan, Sonja Berndt, Jonathan N. Hofmann, Jianxin Shi, Kai Yu, Shahinaz Gadalla, Lisa J. McReynolds, Rena Jones, Hongji Dai, Zhangyan Lyu, Lugui Qiu, Wei Liu, Huilai Zhang, Xianhuo Wang, Lindsay M. Morton, Stephen Chanock, Martha Linet, Melissa C. Friesen, Roel Vermeulen, Nathaniel Rothman. A multi-center hospital-based case-control study of lymphoid and myeloid neoplasms (AsiaLymph): Study design and initial findings for education, body mass index, and family history [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5051.
Abstract 2433: BAP1 loss confers ferroptosis resistance to cholangiocarcinoma via TLCD1-mediated membrane phospholipid remodeling
Zhao, Yu, Classon, Peyton, Carlson, Danielle M. , Millender, Jayla T. , Ilyas, Sumera, Smoot, Rory L., Gores, Gregory J., PATEL, TUSHAR, Povero, Davide , Carlson, Danielle Marie , Yan, Irene K. , Ilyas, Sumera I. , Smoot, Rory L. , Gores, Gregory J.

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2433-2433

10.1158/1538-7445.am2026-2433 Get It

Abstract INTRODUCTION: Cholangiocarcinoma (CCA) is a deadly cancer of the hepatic bile duct epithelial cells. Loss-of-function mutations of epigenetic regulator ubiquitin C-terminal hydrolase deubiquitinase BRCA1-associated protein 1 (BAP1) occur in 26-32% of human CCA and are associated with worse prognosis and resistance to cytotoxic therapy. The goal of this study is to identify how BAP1 loss promotes cell death evasion through metabolic rewiring. MATERIALS & METHODS: Isogenic wild-type and BAP1-deficient human and murine CCA cell lines were generated with shRNA/siRNA or CRISPR/Cas9 and were used to assess ferroptosis sensitivity by treatment with ferroptosis inducers. In vitro, ferroptosis was assessed by phospholipid peroxidation (C-11BODIPY), mitochondrial phospholipid peroxidation (MitoPeDPP, MitoCLox), iron oeverload (MitoFerro green) and cell death (CellTiter-Glo). Phospholipidomics and proteomics were performed in isogenic cells by LC-MS/MS. Isogenic liver orthotopic CCA murine models were used for in vivo pre-clinical studies. RESULTS: Our findings indicate that BAP1 loss confers CCA ferroptosis resistance. BAP1 loss protects CCA against mitochondrial iron overload, ROS accumulation, and phospholipid peroxidation. Strikingly, BAP1 loss protects from mitochondrial phospholipid peroxidation and cardiolipin oxidation. Unbiased phospholipidomic profiling revealed that BAP1 loss remodels membrane phospholipid composition, enriching for ferroptosis-blocking monounsaturated phospholipids (MUFA-PLs) at the expense of ferroptosis-inducing polyunsaturated (PUFA-PLs). We found that BAP1 loss upregulates TLCD1, a phosphatidylethanolamine acyltransferase that incorporates MUFAs into membrane phospholipids, thereby stabilizing membranes against peroxidation. TLCD1 knockdown in BAP1-deficient CCA cells, restored ferroptosis sensitivity Notably, TLCD1 is significantly upregulated in human BAP1-mutant CCA as compared to WT tumors. We identified TLCD1 in the endoplasmic reticulum, Golgi and by mitochondrial outer membrane. In syngeneic liver orthotopic CCA murine models, engineered EpCAM-aptamer-coated lactosomes carrying GPX4 siRNA selectively targeted CCA cells, inducing ferroptosis and robustly suppressing tumor growth without systemic toxicity. Lastly, BAP1-mutant patient-derived xenografts (PDXs) and organoids were resistant to ferroptosis inducers, as compared to WT controls. CONCLUSIONS: Our findings reveal that BAP1 loss rewires mitochondrial phospholipid metabolism thus conferring CCA resistance to ferroptosis, identifying TLCD1 as a targetable metabolic vulnerability in BAP1-mutant CCA. Citation Format: Yu Zhao, Peyton Classon, Danielle Marie Carlson, Jayla Millender, Irene K. Yan, Sumera Ilyas, Rory L. Smoot, Gregory J. Gores, TUSHAR PATEL, Davide Povero. BAP1 loss confers ferroptosis resistance to cholangiocarcinoma via TLCD1-mediated membrane phospholipid remodeling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2433.
Abstract 2483: Survivorship and sexual health: What we learned from Black men in community town halls
Ghasemi, Parisa , Kumar, Gaurav, Ayanambakkam, Adanma, Siston, Amy, Neil, Jordan M., Alexander, Adam, Zhao, Yan D., Dwyer, Kathleen, Young, Mary Ellen , Bolajoko, Opeyemi , Ogunsanya, M., Dwyer, Kathleen , Kumar, Gaurav , Kaninjing, Ernest , Ayanambakkam, Adanma , Nyame, Yaw A. , Neil, Jordan M. , McIntosh, Andrew G. , Nagykáldi, Zsolt , Dickey, Sabrina L. , Morton, Daniel J. , Kendzor, Darla E. , Ogunsanya, Motolani E.

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2483-2483

10.1158/1538-7445.am2026-2483 Get It

Abstract Background: Prostate cancer (CaP) is among the most common cancers in U.S. men, with Black men experiencing a 1.7-fold higher incidence and nearly twice the mortality rate compared with non-Hispanic White men. While early detection has improved survival, differences remain in recovery and quality of life (QoL). Sexual dysfunction after treatment affects identity, relationships, and well-being, yet stigma, cultural norms, and limited access to patient-centered care prevent open discussion. Few initiatives address the intersection of identity, stigma, and survivorship in this population. Community town halls provide a trusted, culturally responsive space for shared learning, peer connection, and open dialogue on survivorship and sexual health. Methods: Two community-engaged CaP town halls were convened by the Multidisciplinary Health Outcomes Research and Economics (MORE) Lab at the University of Oklahoma Health Campus (OUHC) to explore survivorship issues among Black CaP survivors. The first, held virtually in June 2024, included watch parties in Georgia and Texas. The second, in November 2024, was hybrid, hosted at OUHC and via Teams with a watch party at the Willa D. Johnson Recreation Center, a community center in Oklahoma City. Panelists included oncologists, psychologists, survivors, partners, and Community Advisory Board members. Both town halls featured survivor storytelling, provider Q&A, and interactive discussion. Post-event surveys captured demographics, satisfaction, and impact. Open-discussion transcripts were analyzed using Braun and Clarke’s reflexive thematic analysis, guided by a constructivist framework. Results: A total of 124 participants attended both town halls. Survey respondents (n=17; 13.7%) provided demographic and satisfaction data; remaining insights came from all participants who engaged in open dialogue. Respondents ranged in age from 19-76 years (mean=48.7 ± 21.8). Of the 17 respondents, 93% rated the events as very good or excellent; 23.5% were CaP survivors, all identifying as Black. Five themes emerged: (1) Masculinity, stigma, and silence limit help-seeking; (2) Sexual dysfunction and identity loss cause major emotional burdens; (3) Navigation challenges highlight systemic barriers; (4) Spousal and psychological support aid coping; and (5) Survivorship empowerment. Participants valued hearing “real stories from real men,” validating their experiences. Conclusions: Community town halls are a feasible and culturally relevant strategy to engage Black CaP survivors in survivorship and sexual health discussions. By centering lived experiences and facilitating two-way communication between survivors, clinicians, and researchers, these events build trust and reduce stigma. Future work will assess changes in knowledge, engagement, and confidence in care navigation and explore scaling this community-academic model to improve survivorship QoL. Citation Format: Parisa Ghasemi, Gaurav Kumar, Ernest T. Kaninjing, Adanma Ayanambakkam, Yaw A. Nyame, Amy Siston, Jordan M. Neil, Adam C. Alexander, Andrew G. McIntosh, Yan Zhao, Zsolt Nagykaldi, Kathleen A. Dwyer, Mary Ellen Young, Sabrina Dickey, Daniel Morton, Opeyemi Bolajoko, Darla E. Kendzor, Motolani E. Ogunsanya. Survivorship and sexual health: What we learned from Black men in community town halls [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2483.
Predicted versus observed outcomes in the ALT-FLOW early feasibility study
Fioretti, Francesco , Gray, William A, Hibbert, B, Lindenfeld, JoAnn, Tedford, Ryan J, Zahr, Firas, Butler, Javed , Butler, Javed , Gray, William A. , Hibbert, Benjamin , Lindenfeld, JoAnn , Tedford, Ryan J. , Zahr, Firas

ESC Heart Failure | April 3, 2026 | Volume: 13 | Issue: 3 | Pages: No page available

10.1093/eschf/xvag101 | PMID 42257333 Get It

Abstract Background and Aims Whether hemodynamic and symptomatic benefits of the APTURE left atrial-to-coronary sinus shunt translate into clinical outcome benefit in heart failure with left ventricular ejection fraction >40% remains unknown. Methods In this post hoc analysis of ALT-FLOW EFS patients undergoing APTURE implantation, Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score-predicted 1-year all-cause mortality was compared with observed mortality by Kaplan-Meier analysis of adjudicated events. Heart failure hospitalization (HFH) rates were compared for the 12 months before vs after implantation. Additional analyses included stratification by baseline sodium-glucose cotransporter 2 inhibitor (SGLT2i) use and N-terminal pro-B-type natriuretic peptide (NT-proBNP), recurrent HFH cumulative hazard estimation (Nelson-Aalen), and H2FPEF score calculation. Results Among 95 patients (mean age 70.9 ± 8.5 years; 50% women; 93% New York Heart Association Class III; 85.9% with H2FPEF score >3), MAGGIC-predicted 1-year mortality was 13.0%. Observed 1-year survival was significantly higher than predicted (94.7% vs 87.0%; P=0.04), consistent across SGLT2i subgroups (log-rank P=0.59). The proportion of patients with HFH declined from 37.9% pre implantation to 9.6% post implantation (P<0.0001), with event rates falling from 0.61 to 0.21 per patient-year (P<0.001) and a 1-year cumulative hazard of recurrent HFH of 0.19 (95% confidence interval, 0.12-0.31). HFHs were evenly distributed across NT-proBNP strata. Conclusions In ALT-FLOW EFS, observed 1-year mortality was lower than MAGGIC-predicted mortality, and post implantation HFH rates were lower than pre implantation rates. These hypothesis-generating findings will require confirmation in the randomized, sham-controlled ALT-FLOW II trial.
Development of a standard definition of ‘no-option’ and ‘poor-option’ for revascularization in chronic limb-threatening ischemia
Fabiani, Mario Alejandro , Berg, Jos C van den, Torre, Oscar A De la, Verastegui, Alfredo , Dua, Anahita, Alexandrescu, Vlad Adrian, Baadh, Amanjit S. , Bahaa, Nasr, Carvajal, Juan Guillermo Barrera, Beasley, Robert , Bisdas, Theodosios, Blessing, Erwin , Bonvini, Stefano, Brodmann, Marianne, Cabral, Gonçalo, Cancellieri, Roberto, Casini, Andrea , Chandra, Venita , Chisci, Emiliano, Chohan, Omar, Choke, Edward, Chong, Patrick, Clerici, Giacomo , Coscas, Raphaël, Costantino, Del Giudice, D'Oria, Mario, Davies, Robert, Donato, Gianmarco de , Vries, Jean-Paul de , Río-Solá, M.L. del, Deloose, Koen , Dhand, Sabeen , Díaz-Sandoval, Larry J, Falcone, Gianmarco , Fanelli, Fabrizio , Cardona, Lucas Ferrer, Garg, Karan, Giuffrida, Stefania, Gouëffic, Yann, Goverde, Peter , Henao, Esteban, Vegas, Diego Jorge Herrera, Hinchliffe, Robert, Hoballah, Jamal J. , Howard, Dominic, Huasen, Bella , Iida, Osamu, Katsanos, Konstantinos, Kolh, Philippe, Korosoglou, Grigorios, Lecis, Alexandre, Leopoldo, Marine, Lessne, Mark L. , Lichtenberg, Michael, Lobato, Marta , Loreni, Giorgio, Madassery, Kumar, Manzi, Marco, Maene, Lieven, Maresch, Martin, Trabal, Jorge Martinez, Mathews, S Jay, Michael, Siah, J, Bosiers Michel, Migliara, Bruno , Mills, Joseph, Miserlis, Dimitrios , Montero-Baker, Miguel, Alvarez, Luis Morelli, Morgan, Robert Anthony, Mouawad, Nicolas, Moxey, Paul, Antonio, Jose, Nakama, Tatsuya , Neville, Richard, Noronen, Katariina , Palena, Mariano, Parikh, Sahil, Parlani, Gianbattista, Pasqui, Edoardo , Patel, Rafiuddin, Patel, Ashish, Perkov, Dražen , Portou, Mark James, Langhoff, Ralf , Reijnen, Michel Marinus Petrus Johannes, Roy, Trisha , Ruffino, Maria Antonella , Gúzman, Tania Sáez, Sakr, Ahmed, Santini-Domínguez, Rafael , Schmidt, Andrej, Schneider, Peter, Sheorain, Virendersingh K, Siracuse, Jeffrey, Sirvent, Marc , Sommerset, Jill , Spiliopoulos, Stavros, Spinelli, Alessio , Stavroulakis, Konstantinos, Taneva, Gergana T, Teso, Desarom , Thomas, Shannon, Torsello, Giovanni, Tummala, Venkat, Tummala, Srinivas, Twine, Christopher, Uberoi, Raman, Heuvel, Daniel Van den, Varcoe, Ramon Lee, Serrano, José Francisco Vargas, Céniga, Melina Vega de, Venermo, Maarit, Vijaynagar, Badri, Stempel, Conrad von , Voûte, Michiel Thomas, Watts, Mine, Zaefferer, Patricio, Zayed, Hany , Zeebregts, Clark J, Zola, N'Dandu, Mills, Joseph L. , Torre, O. , Verastegui, Alfredo , de la Torre, Oscar , Fabiani, Mario Alejandro , Berg, Jos C. van den , Dua, Anahita , Nasr, Bahaa , Biasi, Lukla , Bisdas, Theodosios , Brodmann, Marianne , Cabral, Gonçalo , Caradu, Caroline , Casini, Andrea , Chisci, Emiliano , Choke, E, Chong, Patrick L.E., Cioppa, Angelo , Coscas, Raphaël , Giudice, Costantino Del , D'Oria, Mario , Peruyera, Pablo Del Canto , Διαμαντόπουλος, Αθανάσιος , Díaz‐Sandoval, Larry J. , Dick, Florian , Fazzini, Stefano , Ferrer, Lucas M. , Fujihara, Masahiko , Garg, Karan , Garriboli, Luca , Genovese, Elizabeth A. , Gifford, Edward D. , Gouëffic, Yann , Gupta, Prem Chand , Vegas, Diego Herrera , Hinchliffe, Robert J. , Holden, Andrew Hugh , Isernia, Giacomo , Kolh, Philippe H. , Korosoglou, Grigorios , Krokidis, Miltiadis E. , Lichtenberg, Michael, Loureiro, Luís , Mathews, S. Jay , Bosiers, Michel Joseph , Morosetti, Daniele , Mouawad, Nicolas J. , Moxey, Paul, Neville, Richard, Palena, Luis Mariano , Parikh, Sahil, Parlani, Gianbattista, Patel, Rafiuddin, Patrone, Lorenzo , Portou, Mark J. , Pratesi, Giovanni , Rammos, Christos , Reijnen, Michel M.P.J. , Sakr, Ahmed , Schneider, Peter A. , Secemsky, Eric A. , Sheorain, Virendersingh K, Simonte, Gioele , Spiliοpoulos, Stavros , Stavroulakis, Konstantinos , Steiner, Sabine , Taneva, Gergana T. , Torsello, Giovanni , Troisi, Nicola , Twine, Christopher P. , Uberoi, Raman , Ucci, Alessandro , Heuvel, Daniel van den, Varcoe, Ramon Lee , Venermo, Maarit A. , Voûte, Michiel T., Ysa, August , Zeebregts, Clark J. , Zeller, Thomas , N'Dandu, Zola M.

British Journal of Surgery | April 3, 2026 | Volume: 113 | Issue: 4 | Pages: No page available

10.1093/bjs/znag040 | PMID 41941595 Get It

Abstract Introduction Revascularization to prevent limb loss is not feasible or represents a very high risk in a significant proportion of patients with chronic limb-threatening ischaemia (CLTI). No standard definition currently exists to define this population of patients. The aim of this study was to develop a consensus-based, multidomain definition to improve clinical assessment and reporting of studies in people with ‘no option’ (NO) or ‘poor option’ (PO) CLTI. Methods A modified Delphi process was conducted with 164 specialists from 30 countries. Two iterative survey rounds were used to reach consensus, defined as ≥70% agreement with a score of ≥7 on a nine-point scale. Results Some 164 international vascular specialists participated in the study, averaging 19 years of experience. A multidomain framework including arterial disease anatomy, biology, risk, function, and context (ABRFC) achieved 83% consensus. A ‘desert foot’ was defined as the absence of distal arterial revascularization targets on advanced non-invasive imaging, invasive digital subtraction angiography, and at least one failed endovascular revascularization attempt (81.6% agreement). Inadequate autogenous bypass conduit was defined as the lack of usable autologous vein across all four limbs (85% agreement). Patients were classified as NO for revascularization if they present with ‘desert foot’, prohibitive medical risk, a non-functional limb, or in those patients who refused arterial revascularization. PO revascularization patients combined factors such as severe infection, lack of autologous vein, or treatment non-compliance (72.1% agreement). Conclusion This consensus study established a structured, expert-validated definition of no option or poor option for revascularisation of patients with CLTI. The multidomain ABRFC framework provides a foundation for standardized clinical assessment, trial design, and future guideline development.
Abstract 4797: Antagonistic SMAD2/3 control of TIMP-1, VEGF-A, and hypoxia signaling in myofibroblasts shapes histotype-specific angiogenesis in lung cancer
Valdivia, Natalia Isabel Diaz, Duch, Paula , Arshakyan, Marselina , Suarez, Alejandro Bernardo, Bernardo, Alejandro , Alcaraz, Jordi , Díaz-Valdivia, Natalia , Parker, Amelia L. , Park, Danielle , Sahai, Erik A. , Reguart, Noemı́ , Radisky, Derek C. , Casanovas, Oriol

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 4797-4797

10.1158/1538-7445.am2026-4797 Get It

Abstract Non-small cell lung cancer (NSCLC) exhibits strikingly different responses to antiangiogenic therapies between its two major histologic subtypes, lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), suggesting an histotype-specific regulation of angiogenesis. Cancer-associated fibroblasts (CAFs) commonly exhibit an activated/myofibroblast-like phenotype in NSCLC, and are emerging as key modulators of tumor progression; however, their contribution to angiogenic control remains undefined. Here, we investigated angiogenesis and hypoxia signatures in NSCLC and integrated bulk RNA-seq, scRNA-seq, CAF secretome profiling, genetic perturbations, and functional in vitro and in vivo assays to dissect the histotype-dependent production of pro-angiogenic factors by CAFs. We observed greater angiogenesis and reduced necrosis/hypoxia in LUAD compared to LUSC across multiple patient cohorts. The LUAD-CAF secretome was primed for angiogenesis through SMAD3-dependent overproduction of key regulators, most notably TIMP-1 and VEGF-A. We also uncovered a previously unrecognized role for TIMP-1 in promoting endothelial hyper-branching. In contrast, LUSC-CAFs displayed attenuated angiogenic activity despite robust HIF-1α upregulation and an hypoxia-associated transcriptional program, due to their epigenetic repression of SMAD3 and compensatory increase in SMAD2. Collectively, these results reveal that CAFs critically shape the distinct angiogenic landscapes of LUAD and LUSC through opposing SMAD2/3 regulation of TIMP-1, VEGF-A, and hypoxia signaling. These results further highlight the therapeutic potential of targeting stromal SMAD3/TIMP-1 in LUAD or microenvironmental stressors such as hypoxia and acidosis in LUSC. In addition, these findings provide a biological framework for understanding histotype-specific patterns of dissemination, immune evasion, and response to antiangiogenic therapies in NSCLC. Citation Format: Jordi Alcaraz, Natalia Isabel Diaz Valdivia, Paula Duch, Marselina Arshakyan, Amelia Parker, Alejandro Bernardo Suarez, Danielle Park, Erik Sahai, Noemi Reguart, Derek C. Radisky, Oriol Casanovas. Antagonistic SMAD2/3 control of TIMP-1, VEGF-A, and hypoxia signaling in myofibroblasts shapes histotype-specific angiogenesis in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4797.
Artificial intelligence-enhanced electrocardiogram for the detection of rheumatic heart disease
Ntsekhe, Mpiko , Harmon, David , Harmon, David M , Ngo, Christie, Ntsekhe, Mpiko , Bhorat, Raeesa, Liu, Kan, Dugan, Jennifer , Ngo, Christie, Friedman, Paul A. , Bagula, Herman, Attia, Zachi I.

European Heart Journal - Digital Health | April 3, 2026 | Volume: 7 | Issue: 4 | Pages: No page available

10.1093/ehjdh/ztag056 | PMID 42077386 Get It

Abstract Aims Rheumatic heart disease (RHD) remains the most prevalent acquired cardiovascular disease among young adults in developing countries, and there is a critical need for an efficient, affordable, and available screening strategy to detect RHD in these resource-limited areas. The 12-lead electrocardiogram (ECG) is a ubiquitous, inexpensive diagnostic tool, and application of artificial intelligence to the ECG (AI-ECG) has allowed for screening of various cardiovascular pathologies. Methods and results Patients aged >18 years with severe RHD with at least one transthoracic echocardiogram and one standard 12-lead ECG performed at Groote Schuur Hospital, Cape Town, within 180 days of each other were eligible. A total of 920 RHD patients were identified, with 2199 corresponding controls from the same medical centre. Patients were allocated to derivation (80%), validation (10%), and testing (10%) groups, respectively. The AI-ECG to detect RHD from a standard 12-lead ECG was built using the Keras framework under Tensorflow backend. In the test group, the AI-ECG for RHD exhibited strong algorithm performance with an AUC of 0.890 (95% Confidence Interval 0.848–0.940) and an accuracy of 83.8%. The algorithm remained robust between RHD presentation: mitral valve alone (AUC 0.913) and mixed mitral and aortic valve disease (AUC 0.858). There were minor performance differences in the subgroup analysis of patient sex, age, and ECG characteristics. Conclusion In this study, an AI-ECG algorithm was successfully developed to screen for advanced RHD from a standard 12-lead ECG, and the AI-ECG performance remained acceptable across most subgroups, including RHD manifestation, patient sex, age <70 years, and ECG characteristics.
Traumatic brain injury recovery prediction by harmonizing real brain CT and synthetic brain MRI: a pilot study
Che, Yiming , Joshi, Amogh Manoj , Shah, Jay , Siddiquee, Md Mahfuzur Rahman , Nikolova, Simona , Li, Baoxin, Rahman Siddiquee, Md Mahfuzur , Chong, Catherine D. , Dumkrieger, Gina , Wu, T. John , Schwedt, Todd J.

Brain Communications | April 3, 2026 | Volume: 8 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcag123 | PMID 42004011 Get It

Abstract To enhance the prediction of traumatic brain injury (mTBI) outcomes, we propose a deep learning approach that integrates brain computed tomography (CT) scans with corresponding synthetic T1-weighted magnetic resonance imaging (T1-MRI). Our method significantly outperforms the prediction using CT scans alone. TRACK-TBI Pilot dataset, which includes imaging and clinical outcome data from patients with TBI, is studied. The hypothesis is brain CT and T1-MRI complement each other and together will improve TBI prognosis compared to using either CT or T1-MRI alone. Since CT and T1-MRI may not be available for the same individual, we employed a specialized version of a generative adversarial network (GAN), known as fixed-point GAN (FP-GAN). FP-GAN was trained using unpaired CT and T1-MRI scans to generate synthetic T1-MRIs from real CT scans. This process produced pseudo-paired CT-MRI data, which was then used to train a deep learning classifier for outcome prediction. The classifier consists of dual parallel 3D ResNet-18 models, each independently processing T1-MRI and CT scans. We used Glasgow Outcome Scale-Extended (GOSE) scores at 3 months post-TBI as the measure of patient outcomes. To avoid data leakage, the subjects used in FP-GAN and ResNet-18 model have no overlap. We further divided the paired data, allocating 69 samples for 5-fold cross-validation and 17 samples for testing. Prognostic performance was evaluated using the area under the receiver operating characteristic curve (AUC), F1-score (the harmonic mean of precision and recall), sensitivity (true positive rate) and specificity (true negative rate). For binary classification, we defined good recovery as GOSE ≥ 7 (positive) and poor recovery (negative) as 3 ≤ GOSE ≤ 6. Accordingly, our training set consists of 24 subjects with poor recovery and 45 subjects with good recovery, while the testing set includes 5 subjects with poor recovery and 12 subjects with good recovery. A DeLong test on AUC confirms that the improvement from incorporating synthetic T1-MRI (AUC = 0.76 ± 0.10) is statistically significant (P < 0.05) compared to using CT alone (AUC = 0.68 ± 0.13). The significant improvement from using the combination of real CT and synthetic T1-MRI in sensitivity (SEN = 0.95 ± 0.07) and overall performance metrics, such as F1-score (F1 = 0.84 ± 0.03), suggests that the proposed approach provides a robust and effective prognostic approach compared to using CT alone (SEN = 0.83 ± 0.18 and F1 = 0.76 ± 0.07). This pilot research demonstrates the potential of a deep learning-based harmonization model to bridge the gap between CT and T1-MRI in TBI assessment. By integrating synthetic T1-MRI with CT, prediction performance is substantially enhanced.